NASDAQ:APGN Apexigen (APGN) Stock Price, News & Analysis → My top 100 stocks… (From DTI) (Ad) Free APGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.39▼$0.3950-Day Range$0.36▼$0.4452-Week Range$0.33▼$8.28VolumeN/AAverage Volume967,731 shsMarket Capitalization$9.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Apexigen alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Apexigen Stock (NASDAQ:APGN)Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.Read More Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him APGN Stock News HeadlinesSeptember 7, 2023 | seekingalpha.comPyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition CompletedAugust 11, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, CPRI, APGNApril 28, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. June 3, 2023 | finance.yahoo.comApexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingMay 27, 2023 | msn.comEF Hutton Reiterates Apexigen (APGN) Hold RecommendationMay 24, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGNMay 17, 2023 | msn.comEF Hutton Maintains Apexigen (APGN) Buy RecommendationMay 16, 2023 | wsj.comAPG SGA S.A.April 28, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. March 3, 2023 | finance.yahoo.comAre Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?March 3, 2023 | finance.yahoo.comAre Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?February 27, 2023 | finance.yahoo.comApexigen Announces Review of Strategic Alternatives and RestructuringJanuary 24, 2023 | finance.yahoo.comApexigen Announces Approximately $2.8 Million Private Placement FinancingJanuary 23, 2023 | msn.comWhy Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving PremarketJanuary 19, 2023 | finance.yahoo.comApexigen Touts New Positive Sotigalimab Data Showing Expanded Anti-Tumor ResponsesJanuary 19, 2023 | benzinga.comThinking about buying stock in Zymeworks, CureVac, Apexigen, Gamida Cell, or Xos?January 19, 2023 | finance.yahoo.comApexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023January 11, 2023 | benzinga.comApexigen Shares Halted On Circuit Breaker To The Upside, Stock Now Up 140.5%November 15, 2022 | finance.yahoo.comApexigen Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 11, 2022 | finance.yahoo.comApexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual MeetingNovember 4, 2022 | bizjournals.comHow biotech companies are building drug pipelines with PIPEsOctober 19, 2022 | msn.comWall Street Set to Open Lower as Higher-Than-Expected UK Inflation Rattles InvestorsOctober 6, 2022 | ca.finance.yahoo.comApexigen, Inc. (APGN)September 12, 2022 | finance.yahoo.comApexigen's Shares Fall After Data From Gastric Cancer CandidateSeptember 10, 2022 | finance.yahoo.comApexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022September 7, 2022 | finance.yahoo.comApexigen to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 5, 2022 | finance.yahoo.comApexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022See More Headlines Receive APGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apexigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APGN CUSIPN/A CIK1814140 Webwww.apexigen.com Phone650-931-6236FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-614.82% Return on Assets-133.30% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-4.28Miscellaneous Outstanding Shares24,862,000Free Float20,088,000Market Cap$9.57 million OptionableNot Optionable Beta3.60 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Xiaodong Yang M.D. (Age 62)Ph.D., CEO & Director Comp: $532.99kMr. Francis W. Sarena (Age 52)Pres & COO Comp: $474.19kDr. Frank J. Hsu M.D. (Age 62)Chief Medical Officer Comp: $520.92kMr. William E. Duke Jr. (Age 51)Chief Financial Officer Ms. Amy Wong (Age 57)Sr. VP of Fin. & Operations Dr. Jason Wright Ph.D.Sr. VP of CMCMore ExecutivesKey CompetitorsMoleculin BiotechNASDAQ:MBRXAeterna ZentarisNASDAQ:AEZSAkari TherapeuticsNASDAQ:AKTXAlterity TherapeuticsNASDAQ:ATHEElevai LabsNASDAQ:ELABView All Competitors This page (NASDAQ:APGN) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apexigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
